

PRO INSTRUMENTS USED IN STUDIES OF SKIN CANCER SINCE 1960

Alison Martin¹

¹Crystallise Ltd, Essex, UK alison.martin@crystallise.com

Objectives

To create an evidence map of the different patient-reported outcome instruments used in studies of patients with skin cancer, the geographical settings in which these studies were conducted and the interventions assessed.

Results Map of studies by publication date

Year	1960-1999	2000-2004	2005-2010	2011-2015	2015-2017
Abstracts	6	17	13	29	14

Methods

We searched the heoro.com database (www.heoro.com) for PRO studies on skin cancer published between 1960 and May 15 2017, and analysed the abstracts identified by the search to determine the different PRO instruments cited across the range of geographical locations and interventions. We presented the findings as an evidence map.

- AKQoL – Actinic Keratosis Quality of Life
- ADQI – Australian Diet Quality Index
- BPI – Brief Pain Inventory
- BSI – Brief Symptom Inventory
- CSQ – Cassileth Scar Questionnaire
- DLQI – Dermatology Life Quality Index
- DQOL – Dermatology Quality of Life Scales
- EORTC QLQ-C30 – European Organization for Research and Treatment of Cancer Quality of Life Core module
- EORTC-melanoma – EORTC melanoma module
- EQ-5D – EuroQoL Questionnaire
- FACT-BR – Functional Assessment of Cancer Therapy – Breast
- FACT-BRM – FACT- Biologic Response Modifiers
- FACT-G – FACT-General
- FACT-M – FACT-Melanoma
- FSCI – Facial Skin Cancer Index
- GHS – Global Health Status
- HADS – Hospital Anxiety and Depression Scale
- HALex – Health Utility Index
- IES – Impact of Event Scale
- LCWS – Lerman's Cancer Worry Scale
- MCSQ – Marlowe-Crowne Social Desirability Scale
- MLQ – McGill Quality of Life Questionnaire
- PAIS-SR – Psychosocial Adjustment of Illness Scale – self report
- POSAS – Patient /Observer Scar Assessment Scale
- POSHN – Patient Outcomes of Surgery – Head/Neck
- POMS – Profile Of Mood States
- QWB-SA – Quality of Well-Being – Self Assessment
- RSES – Rosenberg Self-Esteem Scale
- RSCL – Rotterdam Symptom Checklist
- SF-12 – Short Form 12 items
- SF-36 – Short Form 36 items
- SCI – Skin Cancer Index
- SCQoL – Skin Cancer Quality of Life
- SCQOLIT – Skin Cancer Quality of Life Impact Tool
- SEBI – Sun Exposure and Behaviour Inventory
- STAI – State-Trait Anxiety Inventory
- TSQM – Treatment Satisfaction Questionnaire for Medication
- UKSIP – UK Sickness Impact Profile
- VAS – Visual Analogue Scale
- VSPSQ – Visit-Specific Patient Satisfaction Questionnaire
- VSS – Vancouver Scar Scale
- WOC – Ways of Coping

Map of type of skin cancer by PRO instrument

	aBCCdex	AKQoL	ADQI	BPI	BSI	CSQ	DLQI	DQOL	EORTC QLQ-C30	EORTC-melanoma	EQ-5D	FACT-BR	FACT-BRM	FACT-G	FACT-M	FSCI
Any/ other	0	1	1	0	0	0	1	0	1	0	0	1	0	2	0	0
Melanoma	0	0	0	1	2	1	0	0	12	1	2	0	1	0	4	0
Squamous cell	0	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0
Basal cell	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Non-melanoma	0	0	0	0	0	0	5	1	0	0	0	0	0	2	0	2

	GHS	GSI	HADS	HALex	IES	LCWS	MCSDS	MLQ	PAIS-SR	POSAS	POSHN	POMS	QWB-SA	RSCL	RSES
Any/ other	1	0	0	0	0	0	0	1	0	1	0	0	0	0	0
Melanoma	1	1	3	1	1	0	1	0	1	0	0	1	1	1	0
Squamous cell	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-melanoma	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1

	SF-12	SF-36	SCI	SCQoL	SCQOLIT	SEBI	SKINDEX	STAI	TSQM	UKSIP	VAS	VSPSQ	VSS	WOC	Unclear
Any/ other	0	1	1	0	1	1	1	1	0	1	2	1	1	0	9
Melanoma	0	5	1	0	2	0	3	2	0	0	0	0	0	1	14
Squamous cell	0	0	1	0	0	0	2	0	1	0	2	0	0	0	2
Basal cell	1	0	1	0	0	0	2	0	1	0	2	0	0	0	8
Non-melanoma	2	3	4	1	2	0	2	0	0	0	1	0	1	0	1

Map of geographical location by intervention

	Surgery	Dabrafenib	Dacarbazine	Denileukin	Fotemustine	Imiquimod	Interferon	Intetumumab	Temozolamide	Trametinib	Chemo-therapy	Electro-chemotherapy	Laser therapy	Photo-dynamic therapy	Radio-ablation	Immuno-therapy	Prevention/ surveillance	Other /none
Australia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2
Austria	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Belgium	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0
Canada	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Denmark	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Finland	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Germany	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	1
India	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
International	0	1	1	0	1	0	1	0	1	1	0	0	0	0	0	0	3	3
Italy	1	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0	1
Japan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Netherlands	1	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	1
New Zealand	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Norway	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Spain	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Sweden	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
Switzerland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Taiwan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
UK	3	0	2	0	0	1	2	0	1	0	1	0	1	2	0	0	1	1
USA	9	0	1	1	0	0	2	1	0	0	1	0	0	0	0	0	5	6
Unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Numbers refer to number of studies identified for each category. Where a study is set in two or three locations, these are all listed separately. Studies set in five or more jurisdictions, or systematic reviews are classified as International. Studies are mapped to all relevant subcategories.

Conclusions

A wide range of PRO tools have been used in studies of skin cancer from a wide range of locations, but only six tools and three countries were cited in five or more abstracts.